Amphastar Pharmaceuticals(AMPH)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

AMPH Amphastar Pharmaceuticals

交易中 03-18 15:47:19 EDT

19.04

-0.47

-2.41%

最高19.46	最低19.01	成交量48.71万
今开19.19	昨收19.51	日振幅2.31%
总市值8.64亿	流通市值6.52亿	总股本4,537万
成交额938.73万	换手率1.42%	流通股本3,422万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"AMPH","market":"US","secType":"STK","nameCN":"Amphastar Pharmaceuticals","latestPrice":19.04,"timestamp":1773863235874,"preClose":19.51,"halted":0,"volume":487050,"delay":0,"changeRate":-0.024090210148641843,"floatShares":34222300,"shares":45370171,"eps":2.03,"marketStatus":"交易中","change":-0.47,"latestTime":"03-18 15:47:19 EDT","open":19.19,"high":19.46,"low":19.01,"amount":9387291.139649998,"amplitude":0.023065,"askPrice":19.05,"askSize":376,"bidPrice":19.03,"bidSize":163,"shortable":3,"etf":0,"ttmEps":2.03,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1773864000000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1403668800000,"exchange":"NASDAQ","adjPreClose":19.51,"preHourTrading":{"tag":"盘前","latestPrice":19.5,"preClose":19.51,"latestTime":"09:27 EDT","volume":98932,"amount":1946463.2573880001,"timestamp":1773840447206,"change":-0.01,"changeRate":-0.000513,"amplitude":0.087647},"postHourTrading":{"tag":"盘后","latestPrice":19.51,"preClose":19.51,"latestTime":"18:57 EDT","volume":14379,"amount":280534.7,"timestamp":1773788233098,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.732914,"impliedVol":0.4735,"impliedVolPercentile":0.498},"requestUrl":"/m/hq/s/AMPH","defaultTab":"news","newsList":[{"id":"1170206181","title":"Amphastar Pharmaceuticals宣布增加5000万美元股票回购授权，SEC文件披露2026年3月12日生效","url":"https://stock-news.laohu8.com/highlight/detail?id=1170206181","media":"美股速递","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170206181?lang=zh_cn&edition=full","pubTime":"2026-03-16 18:10","pubTimestamp":1773655839,"startTime":"0","endTime":"0","summary":"根据最新提交给美国证券交易委员会的文件显示，Amphastar Pharmaceuticals公司已于2026年3月12日批准将其股票回购计划规模扩大5000万美元。这一举措显著增强了公司现有的资本回报能力，体现出管理层对自身业务前景和现金流状况的信心。Amphastar Pharmaceuticals此次授权增幅达到5000万美元，反映出公司稳健的财务状况和对未来发展的乐观预期。值得注意的是，该授权生效日期明确设定为2026年3月12日，为公司的资本配置策略提供了明确的时间框架。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMPH","BK4557","BK4588","BK4585","BK4007"],"gpt_icon":0},{"id":"1122614520","title":"Amphastar Pharmaceuticals：依据修正协议，公司将使用汉欣研发的研究细胞库为AMP-105制备主细胞库","url":"https://stock-news.laohu8.com/highlight/detail?id=1122614520","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122614520?lang=zh_cn&edition=full","pubTime":"2026-03-07 05:42","pubTimestamp":1772833357,"startTime":"0","endTime":"0","summary":"根据一项修正协议，Amphastar Pharmaceuticals将采用由汉欣公司开发的研究细胞库，专门用于为在研药物AMP-105制备主细胞库。这一安排旨在推进该候选药物的生产工艺开发。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4557","BK4588","BK4585","AMPH","BK4007"],"gpt_icon":0},{"id":"1156689597","title":"Amphastar Pharmaceuticals与南京医药签署供应协议，合作方为南京莱拓生物科技","url":"https://stock-news.laohu8.com/highlight/detail?id=1156689597","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156689597?lang=zh_cn&edition=full","pubTime":"2026-03-07 05:42","pubTimestamp":1772833340,"startTime":"0","endTime":"0","summary":"根据美国证券交易委员会（SEC）最新披露的文件，Amphastar Pharmaceuticals（AMPH）旗下南京医药于3月3日与南京莱拓生物科技有限公司正式达成供应合作协议。该协议的签署标志着双方在医药产品供应链领域建立起战略性合作关系。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4557","BK4585","BK4588","AMPH","BK4007"],"gpt_icon":0},{"id":"1194133320","title":"Amphastar Pharmaceuticals与南京汉欣医药科技签署合同研究协议修正案","url":"https://stock-news.laohu8.com/highlight/detail?id=1194133320","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194133320?lang=zh_cn&edition=full","pubTime":"2026-03-07 05:42","pubTimestamp":1772833338,"startTime":"0","endTime":"0","summary":"3月3日，Amphastar Pharmaceuticals公司与南京汉欣医药科技有限公司共同签署了合同研究协议的修正案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4585","BK4588","AMPH","BK4557"],"gpt_icon":0},{"id":"1175736263","title":"异动解读 | 杰富瑞下调目标价，Amphastar Pharmaceuticals盘中大跌15.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=1175736263","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175736263?lang=zh_cn&edition=full","pubTime":"2026-02-27 22:38","pubTimestamp":1772203133,"startTime":"0","endTime":"0","summary":"Amphastar Pharmaceuticals（AMPH）今日盘中股价大幅下跌15.29%，引起了市场的广泛关注。消息面上，根据路透社报道，华尔街知名券商杰富瑞（Jefferies）在周五发布的研究报告中，将Amphastar Pharmaceuticals的目标价从38美元下调至30美元。分析师下调目标价通常反映了对公司未来业绩增长或估值预期的审慎看法，这被视为导致该股在今日交易时段内承压下跌的主要原因。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AMPH"],"gpt_icon":0},{"id":"1115420924","title":"异动解读 | 杰富瑞下调目标价，Amphastar Pharmaceuticals盘前大跌14.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=1115420924","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115420924?lang=zh_cn&edition=full","pubTime":"2026-02-27 20:03","pubTimestamp":1772193792,"startTime":"0","endTime":"0","summary":"Amphastar Pharmaceuticals（AMPH）今日盘前股价大幅下跌14.68%，引起了市场的关注。消息面上，根据路透社报道，华尔街券商杰富瑞（Jefferies）在周五发布的研究报告中，将Amphastar Pharmaceuticals的目标价从38美元下调至30美元。分析师下调目标价通常反映了对公司未来业绩或估值预期的调整，这可能是导致该股在盘前交易时段承压下跌的主要原因。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AMPH"],"gpt_icon":0},{"id":"2608159598","title":"Amphastar Pharmaceuticals, Inc.盘中异动 下午盘股价大涨5.30%报27.90美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608159598","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608159598?lang=zh_cn&edition=full","pubTime":"2026-02-03 03:08","pubTimestamp":1770059286,"startTime":"0","endTime":"0","summary":"北京时间2026年02月03日03时08分，Amphastar Pharmaceuticals, Inc.股票出现波动，股价快速上涨5.30%。Amphastar Pharmaceuticals, Inc.股票所在的制药行业中，整体涨幅为0.50%。Amphastar Pharmaceuticals, Inc.公司简介：Amphastar Pharmaceuticals Inc 是一家生物制药公司，专注于开发，制造，营销和销售技术上具有挑战性的仿制和专有注射，吸入和鼻内产品，以及胰岛素活性药物成分产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260203030806a6cb4253&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260203030806a6cb4253&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AMPH","BK4557","BK4588","BK4585","BK4007"],"gpt_icon":0},{"id":"1186841287","title":"Amphastar Pharmaceuticals与南京汉欣医药科技就全合成促肾上腺皮质激素化合物达成授权协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1186841287","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186841287?lang=zh_cn&edition=full","pubTime":"2026-01-12 19:05","pubTimestamp":1768215918,"startTime":"0","endTime":"0","summary":"Amphastar Pharmaceuticals已同南京汉欣医药科技有限公司签署一项授权协议，涉及一款全合成促肾上腺皮质激素化合物的开发与商业化。该合作旨在拓展双方在激素类药物领域的产品管线，为特定内分泌疾病患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4557","BK4588","BK4585","AMPH","BK4007"],"gpt_icon":0},{"id":"1170023421","title":"安菲斯塔制药：FDA认定公司的特立帕肽与礼来公司的Forteo具有生物等效性和治疗等效性","url":"https://stock-news.laohu8.com/highlight/detail?id=1170023421","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170023421?lang=zh_cn&edition=full","pubTime":"2025-12-15 19:05","pubTimestamp":1765796711,"startTime":"0","endTime":"0","summary":"安菲斯塔制药：FDA认定公司的特立帕肽与礼来公司的Forteo具有生物等效性和治疗等效性","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BK4007","BK4557","AMPH"],"gpt_icon":0},{"id":"1193841528","title":"安菲斯塔制药公司：巴克莱开始覆盖，并给予平等权重评级；目标价格为30美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1193841528","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193841528?lang=zh_cn&edition=full","pubTime":"2025-12-09 19:43","pubTimestamp":1765280592,"startTime":"0","endTime":"0","summary":"安菲斯塔制药公司：巴克莱开始覆盖，并给予平等权重评级；目标价格为30美元","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4007","AMPH","BK4588","BK4557"],"gpt_icon":0},{"id":"1107524050","title":"Amphastar Pharmaceuticals Inc - 协议期限为10年，且可进行续签谈判 - SEC备案","url":"https://stock-news.laohu8.com/highlight/detail?id=1107524050","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107524050?lang=zh_cn&edition=full","pubTime":"2025-10-25 04:24","pubTimestamp":1761337451,"startTime":"0","endTime":"0","summary":"Amphastar Pharmaceuticals Inc - 协议期限为10年，且可进行续签谈判 - SEC备案","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4557","BK4007","BK4588","BK4585","AMPH"],"gpt_icon":0},{"id":"1144182770","title":"Amphastar Pharmaceuticals任命成都作为Baqsimi在大中华区的独家经销商 - SEC备案","url":"https://stock-news.laohu8.com/highlight/detail?id=1144182770","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144182770?lang=zh_cn&edition=full","pubTime":"2025-10-25 04:24","pubTimestamp":1761337451,"startTime":"0","endTime":"0","summary":"Amphastar Pharmaceuticals任命成都作为Baqsimi在大中华区的独家经销商 - SEC备案","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4588","BK4585","AMPH","BK4557"],"gpt_icon":0},{"id":"1193463099","title":"Amphastar Pharmaceuticals Inc - 10月21日，公司旗下与程工达成分销协议 - SEC文件","url":"https://stock-news.laohu8.com/highlight/detail?id=1193463099","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193463099?lang=zh_cn&edition=full","pubTime":"2025-10-25 04:24","pubTimestamp":1761337451,"startTime":"0","endTime":"0","summary":"Amphastar Pharmaceuticals Inc - 10月21日，公司旗下与程工达成分销协议 - SEC文件","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4557","BK4588","AMPH","BK4007","BK4585"],"gpt_icon":0},{"id":"1185680615","title":"Amphastar Pharmaceuticals与Hanxin签署合同研究协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1185680615","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185680615?lang=zh_cn&edition=full","pubTime":"2025-09-19 04:49","pubTimestamp":1758228559,"startTime":"0","endTime":"0","summary":"Amphastar Pharmaceuticals于9月15日与Hanxin签署了一项合同研究协议。该协议的签署标志着两家公司在研发领域的合作关系正式建立。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","AMPH","BK4007","BK4585","BK4557"],"gpt_icon":0},{"id":"2517149430","title":"Amphastar Pharmaceuticals, Inc.2024财年实现净利润1.60亿美元，同比增加15.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517149430","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517149430?lang=zh_cn&edition=full","pubTime":"2025-03-08 00:00","pubTimestamp":1741363258,"startTime":"0","endTime":"0","summary":"3月8日，Amphastar Pharmaceuticals, Inc.公布财报，公告显示公司2024财年净利润为1.60亿美元，同比增加15.94%；其中营业收入为7.32亿美元，同比增加13.66%，每股基本收益为3.29美元。从资产负债表来看，Amphastar Pharmaceuticals, Inc.总负债8.92亿美元，其中短期债务7.04百万美元，资产负债比为1.83，流动比率为3.07。机构评级：截至2025年3月8日，当前有5家机构对Amphastar Pharmaceuticals, Inc.目标价做出预测，其中目标均价为39.80美元，其中最低目标价为36.00美元，最高目标价为45.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000250a2647fca&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000250a2647fca&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AMPH"],"gpt_icon":0},{"id":"2516657112","title":"Amphastar Pharmaceuticals, Inc.盘中异动 下午盘大幅跳水5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516657112","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516657112?lang=zh_cn&edition=full","pubTime":"2025-03-04 03:04","pubTimestamp":1741028653,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日03时04分，Amphastar Pharmaceuticals, Inc.股票出现异动，股价快速下挫5.06%。Amphastar Pharmaceuticals, Inc.股票所在的制药行业中，整体涨幅为1.04%。Amphastar Pharmaceuticals, Inc.公司简介：Amphastar Pharmaceuticals Inc 是一家生物制药公司，专注于开发、制造、营销和销售技术上具有挑战性的仿制和专有注射、吸入和鼻内产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304030413abe67f78&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304030413abe67f78&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AMPH","BK4588","BK4585","BK4557","BK4007"],"gpt_icon":0},{"id":"2514320118","title":"Amphastar Pharmaceuticals, Inc.盘中异动 股价大跌5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514320118","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514320118?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:37","pubTimestamp":1740753470,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日22时37分，Amphastar Pharmaceuticals, Inc.股票出现波动，股价快速下跌5.02%。Amphastar Pharmaceuticals, Inc.股票所在的制药行业中，整体涨幅为0.18%。其相关个股中，Organogenesis Holdings Inc.、百利高、Ani Pharmaceuticals, Inc.涨幅较大，Organogenesis Holdings Inc.、大自然药业、Petros Pharmaceuticals, Inc.较为活跃，换手率分别为3.94%、2.57%、2.29%，振幅较大的相关个股有Organogenesis Holdings Inc.、Talphera, Inc.、Evoke Pharma, Inc.，振幅分别为46.58%、8.63%、7.47%。Amphastar Pharmaceuticals, Inc.公司简介：Amphastar Pharmaceuticals Inc 是一家生物制药公司，专注于开发、制造、营销和销售技术上具有挑战性的仿制和专有注射、吸入和鼻内产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022822375198967b76&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022822375198967b76&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AMPH","BK4585","BK4557","BK4007","BK4588"],"gpt_icon":0},{"id":"1188065952","title":"异动解读 | Amphastar Pharmaceuticals发布2024年第四季度业绩不佳,盘后股价大跌10.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=1188065952","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188065952?lang=zh_cn&edition=full","pubTime":"2025-02-28 06:06","pubTimestamp":1740693993,"startTime":"0","endTime":"0","summary":"Amphastar Pharmaceuticals公司(纳斯达克代码:AMPH)2024年第四季度财报业绩不佳,触发其在盘后交易中大幅下跌10.19%。\n\n根据公司公布的最新财报,Amphastar 2024年第四季度调整后每股收益为0.92美元,低于分析师预期的0.94美元。季度销售额达1.865亿美元,也未能达到预期的1.888亿美元目标。\n\n公司每股收益和营收均未达预期,引发市场对其盈利能力和增长前景的质疑。分析人士指出,该公司可能面临来自仿制药竞争加剧、新药研发进展缓慢、或营运成本过高等挑战。投资者对Amphastar的长期发展潜力失去信心,从而导致股价在盘后交易中大幅下挫。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AMPH"],"gpt_icon":0},{"id":"1157836861","title":"Amphastar制药2024年第四季度调整后每股收益为0.92美元,低于预期的0.94美元，销售额为1.865亿美元，未达到预期的1.888亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1157836861","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157836861?lang=zh_cn&edition=full","pubTime":"2025-02-28 05:18","pubTimestamp":1740691127,"startTime":"0","endTime":"0","summary":"Amphastar制药报告其季度每股收益为0.92美元，低于分析师预期的0.94美元，相差2.13%。这是其上一年同期每股收益0.88美元的基础上增长了4.55%。与去年同期1.78105亿美元的销售额相比，该季度销售额增长了4.71%。以上内容来自Benzinga Earnings专栏，原文如下：Amphastar Pharma  reported quarterly earnings of $0.92 per share which missed the analyst consensus estimate of $0.94 by 2.13 percent. This is a 4.55 percent increase over earnings of $0.88 per share from the same period last year.  The company reported quarterly sales of $186.500 million which missed the analyst consensus estimate of $188.810 mill","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Amphastar制药2024年第四季度调整后每股收益为0.92美元,低于预期的0.94美元，销售额为1.865亿美元，未达到预期的1.888亿美元","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMPH"],"gpt_icon":0},{"id":"2508366634","title":"Piper Sandler：下调Amphastar Pharma(AMPH.US)评级，由增持调整至中性评级, 目标价由66.00美元调整至36.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2508366634","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2508366634?lang=zh_cn&edition=full","pubTime":"2025-02-04 17:25","pubTimestamp":1738661109,"startTime":"0","endTime":"0","summary":"Piper Sandler：下调Amphastar Pharma(AMPH.US)评级，由增持调整至中性评级, 目标价由66.00美元调整至36.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/04172547948721.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["AMPH"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.amphastar.com","stockEarnings":[{"period":"1week","weight":0.0317},{"period":"1month","weight":-0.3154},{"period":"3month","weight":-0.2516},{"period":"6month","weight":-0.289},{"period":"1year","weight":-0.2954},{"period":"ytd","weight":-0.2715}],"compareEarnings":[{"period":"1week","weight":-0.0094},{"period":"1month","weight":-0.0161},{"period":"3month","weight":-0.0009},{"period":"6month","weight":0.0129},{"period":"1year","weight":0.1827},{"period":"ytd","weight":-0.0163}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Amphastar Pharmaceuticals, Inc.是一家加利福尼亚的公司，成立于1996年2月29日，于2004年7月和amphastar制药公司一家在特拉华成立的公司合并。公司是一家专业制药公司，主要开发，生产，销售市场上通用和专用注射和吸入产品，包括投资组合的市场进入壁垒高，通用和专利产品。大多数公司的产品用于住院或紧急护理的临床设置和主要承包通过集团采购组织和药品批发商。公司的产品主要分布在药企零售。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.032842},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.035845},{"month":3,"riseRate":0.583333,"avgChangeRate":0.033146},{"month":4,"riseRate":0.454545,"avgChangeRate":-0.006986},{"month":5,"riseRate":0.818182,"avgChangeRate":0.067588},{"month":6,"riseRate":0.636364,"avgChangeRate":0.056362},{"month":7,"riseRate":0.5,"avgChangeRate":-0.004743},{"month":8,"riseRate":0.583333,"avgChangeRate":0.055341},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.045989},{"month":10,"riseRate":0.416667,"avgChangeRate":-0.011073},{"month":11,"riseRate":0.75,"avgChangeRate":0.073289},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.000354}],"exchange":"NASDAQ","name":"Amphastar Pharmaceuticals","nameEN":"Amphastar Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Amphastar Pharmaceuticals(AMPH)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Amphastar Pharmaceuticals(AMPH)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Amphastar Pharmaceuticals,AMPH,Amphastar Pharmaceuticals股票,Amphastar Pharmaceuticals股票老虎,Amphastar Pharmaceuticals股票老虎国际,Amphastar Pharmaceuticals行情,Amphastar Pharmaceuticals股票行情,Amphastar Pharmaceuticals股价,Amphastar Pharmaceuticals股市,Amphastar Pharmaceuticals股票价格,Amphastar Pharmaceuticals股票交易,Amphastar Pharmaceuticals股票购买,Amphastar Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Amphastar Pharmaceuticals(AMPH)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Amphastar Pharmaceuticals(AMPH)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}